Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Post-ASCO & EHA 2023 MDS Highlights
22 June 2023 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in MDS from ASCO and EHA 2023
Covering updates in MDS classification, treatment beyond ESAs, and disease modification.
Session 1: MDS classification
Classification from WHO 2017-2022 and ICC 2022
Rami Komrokji H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Panel discussion
Session 2: Treatment beyond ESAs
COMMANDS trial: Luspatercept vs EPO alfa for lower-risk MDS
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
KER-050 treatment for lower-risk MDS
Thomas Cluzeau Central University Hospital of Nice, France
IMerge trial: Imetelstat for LR-MDS R/R to ESAs
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Disease modifying activity of imetelstat from the IMerge trial
Valeria Santini University of Florence, Florence, Italy
Panel discussion
Session 3: Disease Modification
Decitabine/cedazuridine + venetoclax for treatment-naïve HR-MDS or CMML
Alexander Bataller North Carolina State University, Raleigh, NC, United States
Safety and efficacy of decitabine/cedazuridine in LR-MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Ivosidenib in IDH1m R/R MDS
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Myeloid NGS analyses of paired samples from BM and PB
Lisa Pleyer Paracelsus Medical University, Salzberg, Austria
Panel discussion
The Post-ASCO & EHA 2023 MDS Highlights webinar has been supported by:
Platinum Supporters
Silver Supporters
